Were Evan Lippman’s TEVA share sales under a Rule 10b5-1 plan?

Yes. A footnote states the reported transaction was effected under a Rule 10b5-1 trading plan adopted on November 10, 2025 . Such plans pre-schedule trades, making the timing more routine and less discretionary.

Did any of Evan Lippman’s TEVA share sales cover tax withholding obligations?

Yes. A footnote explains that part of the reported sale represents shares required to be sold to cover tax withholding obligations tied to the vesting of the restricted share units listed in Table II.

What future vesting schedule is disclosed for Evan Lippman’s TEVA restricted share units?

Footnotes describe RSUs granted on May 14, 2025 , with 11,841 units vesting annually on May 14, 2027 and May 14, 2028 , and 11,842 units on May 14, 2029 , plus additional tranches of 37,004 units vesting in 2027 and 2028 .

TEVA (TEVA) EVP Lippman exercises 85,849 RSUs and sells 41,658 shares

Q: How many TEVA shares did Evan Lippman sell and at what price range?

He sold 41,658 Ordinary Shares of TEVA at a weighted average price of $35.5842 per share. A footnote explains these shares were sold in multiple trades between $35.38 and $35.685 per share.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

TEVA PHARMACEUTICAL INDUSTRIES LTD EVP, Business Development Evan Lippman reported an exercise-and-sell transaction in company stock. On May 14, 2026, he exercised restricted share units to acquire 85,849 Ordinary Shares at a conversion price of $0.00 per share.

On the same date, he sold a total of 41,658 Ordinary Shares at a weighted average price of $35.5842 per share, with individual sale prices ranging from $35.38 to $35.685. A footnote states that a portion of the sold shares was required to cover tax withholding obligations related to the RSU vesting, and that the transactions were executed under a pre-arranged Rule 10b5-1 trading plan.

Insider Trade Summary 10b5-1

Net Seller: 41,658 shares ($1,482,367)

Net Sell 6 txns

Insider Lippman Evan

Role EVP, Business Development

Sold 41,658 shs ($1.48M)

Type	Security	Shares	Price	Value
Exercise	Restricted Share Units	11,841	$0.00	--
Exercise	Restricted Share Units	74,008	$0.00	--
Exercise	Ordinary Shares	11,841	$0.00	--
Sale	Ordinary Shares	5,746	$35.5842	$204K
Exercise	Ordinary Shares	74,008	$0.00	--
Sale	Ordinary Shares	35,912	$35.5842	$1.28M

Holdings After Transaction: Restricted Share Units — 35,524 shares (Direct, null); Ordinary Shares — 11,841 shares (Direct, null)

Footnotes (1)

The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.38 to $35.685, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price. Restricted share units were granted on May 14, 2025, with 11,841 vested on May 14, 2026, 11,841 vesting on each of May 14, 2027 and May 14, 2028, and 11,842 vesting on May 14, 2029. Restricted share units were granted on May 14, 2025, with 74,008 vested on May 14, 2026, and 37,004 vesting on each of May 14, 2027 and May 14, 2028.

Key Figures

Shares sold: 41,658 shares Weighted average sale price: $35.5842 per share Sale price range: $35.38–$35.685 per share +3 more

6 metrics

Shares sold 41,658 shares Ordinary Shares sold on May 14, 2026

Weighted average sale price $35.5842 per share Ordinary Share sales on May 14, 2026

Sale price range $35.38–$35.685 per share Multiple sale transactions on May 14, 2026

Shares from RSU exercises 85,849 shares Ordinary Shares acquired via RSU exercises on May 14, 2026

RSU grant vesting (11,841 units) 11,841 units per year Vest on May 14, 2027 and 2028; 11,842 on May 14, 2029

RSU grant vesting (37,004 units) 37,004 units per year Vest on May 14, 2027 and May 14, 2028

Key Terms

Rule 10b5-1 trading plan, restricted share units, weighted average price, American Depositary Shares, +1 more

5 terms

Rule 10b5-1 trading plan financial

"The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025."

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.38 to $35.685, inclusive."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

American Depositary Shares financial

"The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share."

American depositary shares (ADSs) are a way for investors in the United States to buy shares of foreign companies without dealing with international markets directly. They represent ownership in a foreign company's stock and are traded on U.S. stock exchanges, making it easier for American investors to buy, sell, and own parts of companies from around the world.

tax withholding obligations financial

"Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II."

Form 4 Insider Transactions: What Each Field Means →

05/18/2026 - 04:02 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lippman Evan

(Last)

(First)

(Middle)

C/O TEVA PHARMACEUTICAL INDUSTRIES LTD.

124 DVORA HANEVI'A ST.,

(Street)

TEL AVIV

ISRAEL

6944020

(City)

(State)

(Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
TEVA PHARMACEUTICAL INDUSTRIES LTD [ TEVA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	EVP, Business Development

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/14/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Ordinary Shares⁽¹⁾	05/14/2026		M		11,841	A	⁽²⁾	11,841	D
Ordinary Shares⁽¹⁾	05/14/2026		S⁽³⁾		5,746⁽⁴⁾	D	$35.5842⁽⁵⁾	6,095	D
Ordinary Shares⁽¹⁾	05/14/2026		M		74,008	A	⁽²⁾	80,103	D
Ordinary Shares⁽¹⁾	05/14/2026		S⁽³⁾		35,912⁽⁴⁾	D	$35.5842⁽⁵⁾	44,191	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Share Units	⁽²⁾	05/14/2026		M			11,841	⁽⁶⁾	⁽⁶⁾	Ordinary Shares⁽¹⁾	11,841	$0	35,524	D
Restricted Share Units	⁽²⁾	05/14/2026		M			74,008	⁽⁷⁾	⁽⁷⁾	Ordinary Shares⁽¹⁾	74,008	$0	74,008	D

Explanation of Responses:

1. The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.

2. Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the option of the Human Resources and Compensation Committee, the cash value of one ordinary share.

3. The transaction reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 10, 2025.

4. Represents the number of shares required to be sold by the reporting person to cover tax withholding obligations in connection with the vesting of the restricted share units listed in Table II.

5. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.38 to $35.685, inclusive. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or any security holder of the issuer, full information regarding the number of shares sold at each separate price.

6. Restricted share units were granted on May 14, 2025, with 11,841 vested on May 14, 2026, 11,841 vesting on each of May 14, 2027 and May 14, 2028, and 11,842 vesting on May 14, 2029.

7. Restricted share units were granted on May 14, 2025, with 74,008 vested on May 14, 2026, and 37,004 vesting on each of May 14, 2027 and May 14, 2028.

	/s/ Dov Bergwerk as attorney-in-fact for Evan Lippman	05/18/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did TEVA EVP Evan Lippman report on this Form 4?

Lippman reported both exercises and sales of TEVA shares. He exercised restricted share units into 85,849 Ordinary Shares and sold 41,658 Ordinary Shares on May 14, 2026, combining compensation-related activity with stock sales.

How many TEVA shares did Evan Lippman sell and at what price range?

He sold 41,658 Ordinary Shares of TEVA at a weighted average price of $35.5842 per share. A footnote explains these shares were sold in multiple trades between $35.38 and $35.685 per share.

What RSU exercises did TEVA EVP Evan Lippman report in this filing?

Lippman exercised restricted share units that converted into 85,849 Ordinary Shares at a conversion price of $0.00 per share. These RSUs are part of prior equity awards that vested and settled into TEVA Ordinary Shares on May 14, 2026.